Recent advances in the treatment of RCC have been made based on improved understanding of the molecular biology of this disease, including the involvement of pathways linked to the vascular endothelial growth factor receptor (VEGFR), mammalian target of rapamycin (mTOR), and the programmed cell death (PD-1) receptor [4–6]. This evidence concerns the gene KDR and renal cell carcinoma.